Taipei, Dec. 30 (CNA) A new drug targeted at preventing the recurrence of liver cancer after it is treated surgically is expected to receive approval in most Asian countries by 2015, according to the company authorized to develop, produce and market the drug.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Society
Taipei 101 launches 3-month campaign to celebrate the new year
12/04/2020 07:47 PM - Society
CECC mulls harsher punishments for flight crew who break quarantine
12/04/2020 07:44 PM - Cross-Strait
Three Chinese military planes enter Taiwan's ADIZ
12/04/2020 07:38 PM - Culture
Pianist Kun-Woo Paik to play rearranged Beethoven sonata cycle
12/04/2020 07:08 PM - Science & Tech
TSMC vows to work closely with suppliers in 3nm process development
12/04/2020 06:51 PM
